Monopar Therapeutics Inc. – Consensus Indicates Potential 437.8% Upside

Broker Ratings

Monopar Therapeutics Inc. with ticker code (MNPR) have now 3 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 40 and 11 with a mean TP of 30.33. Given that the stocks previous close was at 5.64 this would indicate that there is a potential upside of 437.8%. The day 50 moving average is 5.06 while the 200 day moving average is 6.05. The company has a market cap of $69m. You can visit the company’s website by visiting: http://www.monopartx.com

Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen). Share on:

Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on facebook
Facebook
Share on email
Email
Share on reddit
Reddit

AIM All Share Index